https://mb.cision.com/Public/18595/3626545/96782afa209d40cc_800x800ar.png
** New Three-Year BIMZELX^=C2=AE=E2=96=BC (bimekizumab) Data Reinforce Long=
-Term Maintenance of Complete Skin Clearance in Moderate to Severe Plaque P=
soriasis
------------------------------------------------------------
=C2=B7 Three-year data from the BE BRIGHT open-label extension study are be=
ing presented at the 31st EADV Congress =C2=A0
=C2=B7 Over eight out of 10 patients who achieved complete skin clearance (=
PASI 100) at week 16 maintained PASI 100 responses and health-related quali=
ty of life outcomes through to three years=C2=A0
=C2=B7 Analysis of pooled safety data from up to three years of treatment i=
n Phase 2 and 3 clinical trials showed bimekizumab was generally well toler=
ated with no new safety signals identified over three years
Brussels (Belgium), 7th September 2022 =E2=80=93 07:00 (CEST) =E2=80=93 UCB=
, a global biopharmaceutical company, today announced new three-year result=
s from the BE BRIGHT open-label extension (OLE) study evaluating the long-t=
erm safety, tolerability and efficacy of BIMZELX^=C2=AE (bimekizumab) in ad=
ults with moderate to severe plaque psoriasis who completed one of three pi=
votal Phase 3 studies.^1 These data, together with a three-year safety anal=
ysis of pooled data from Phase 2 and Phase 3 studies^2 are being presented =
at the 31st European Academy of Dermatology and Venereology (EADV) Congress=
in Milan, Italy, September 7=E2=80=9310. A total of eleven abstracts highl=
ighting data related to bimekizumab in psoriasis are being presented at the=
congress.
Bimekizumab is the first selective IL-17A and IL-17F inhibitor to be approv=
ed in the European Union for the treatment of moderate to severe plaque pso=
riasis in adults who are candidates for systemic therapy.^3
Data presented from the BE BRIGHT OLE study showed that over eight out of 1=
0 patients who achieved complete skin clearance (PASI 100) following 16 wee=
ks of bimekizumab treatment maintained PASI 100 response and health-related=
quality of life outcomes through to three years with continuous maintenanc=
e dosing.* In addition, approximately nine out of 10 patients who achieved =
absolute PASI (PASI =E2=89=A42) at week 16 maintained this response through=
to three years.^1 Pooled data from up to three years of treatment in Phase=
2 and 3 clinical trials showed that bimekizumab was generally well-tolerat=
ed over this period with no safety signals identified.^2
=E2=80=9CThese positive results highlight the deep and long-lasting skin cl=
earance achieved with bimekizumab, along with a consistent safety and toler=
ability profile, and reinforce the positive relationship clearing skin has =
on patients=E2=80=99 quality of life. These new data add to the growing bod=
y of evidence supporting longer-term use of bimekizumab in moderate to seve=
re plaque psoriasis,=E2=80=9D said Emmanuel Caeymaex, Executive Vice Presid=
ent, Immunology Solutions and Head of U.S., UCB.=C2=A0
=E2=80=9CThe findings presented today show that bimekizumab provided mainte=
nance of completely clear skin and health-related quality of life outcomes =
in the majority of patients with moderate to severe plaque psoriasis over a=
three-year period,=E2=80=9D said Dr Bruce Strober, Clinical Professor of D=
ermatology at Yale University, Connecticut, U.S. =E2=80=9CThe goal of psori=
asis treatment often is complete clearance of skin symptoms and the availab=
ility of long-term data across treatment options is important since it supp=
orts healthcare providers and patients to be more informed when making trea=
tment decisions.=E2=80=9D
Three-year data from the BE BRIGHT OLE study
All patients who had completed one of the pivotal Phase 3 studies (BE SURE,=
BE VIVID and BE READY) were eligible to enter the BE BRIGHT OLE study.^1 O=
n OLE entry, patients were assigned to bimekizumab 320 mg every four weeks =
(Q4W) or every eight weeks (Q8W) based on PASI 90 response at the end of th=
e respective Phase 3 study.=C2=A0
=C2=A0In all bimekizumab-randomized patients:^1=C2=A5
=C2=B7 Among week 16 PASI 100 responders (N=3D503), 89.3 percent achieved P=
ASI 100 at year one (week 52) and 82.0 percent at year three (OLE week 96)
=C2=B7 Among week 16 PASI =E2=89=A42 responders (N=3D694), 96.5 percent ach=
ieved PASI =E2=89=A42 at year one (week 52) and 94.2 percent at year three =
(OLE week 96)
=C2=B7 Among week 16 PASI 100 responders in BE SURE and BE READY only (N=3D=
330), 92.0 percent achieved the Dermatology Life Quality Index (DLQI) 0/1 a=
t year one (week 56), and 88.0 percent at year three (OLE week 96)
In bimekizumab-randomized patients (320 mg Q4W for 16 weeks, and then every=
eight weeks [Q8W] through three years, BE SURE and BE READY only):^1=C2=A5
=C2=B7 Among week 16 PASI 100 responders (N=3D147), 93.6 percent achieved P=
ASI 100 at year one (week 52) and 84.4 percent at year three (OLE week 96)
=C2=B7 Among week 16 PASI =E2=89=A42 responders (N=3D189), 98.9 percent ach=
ieved PASI =E2=89=A42 at year one (week 52) and 96.8 percent at year three =
(OLE week 96)
=C2=B7 Among week 16 PASI 100 responders (N=3D147), 95.8 percent achieved D=
LQI 0/1 at year one (week 56) and 92.5 percent at year three (OLE week 96)
Pooled safety data from up to three years of treatment in Phase 2 and 3 cli=
nical trials
Total bimekizumab exposure was 4245.3 patient-years (PY; N=3D1789) across t=
he Phase 2 and 3 trials, and 3876.4 PY (N=3D1495; Q4W: 1965.6 PY; Q8W: 1914=
.5 PY) in the Phase 3 trials.^2 Treatment emergent adverse events (TEAEs) o=
ccurred at an exposure-adjusted incidence rate (EAIR) of 186.1 per 100 PY, =
serious TEAEs were seen at an EAIR of 5.6 new cases per 100 PY and TEAEs le=
ading to discontinuation at 3.5 new cases per 100 PY.^2=C2=A0
The most common TEAEs in the Phase 2 and 3 trials with bimekizumab were nas=
opharyngitis, oral candidiasis and upper respiratory tract infection at EAI=
Rs of 15.3, 10.2 and 7.1 new cases per 100 PY, respectively.^2 The EAIR for=
oral candidiasis showed a decrease compared with two years of bimekizumab =
treatment (10.2 versus 12.6 new cases per 100 PY) and was lower with bimeki=
zumab dosed Q8W compared with Q4W (7.1 and 15.9 per 100 PY, respectively).^=
2 =C2=A0The vast majority of oral candidiasis events were mild to moderate =
(99.4 percent) and none were serious.^2 Serious infections occurred at a ra=
te of 1.2/100 PY. The most frequently reported were serious coronavirus inf=
ections (0.2 per 100 PY).^2=C2=A0
*The recommended bimekizumab dose for adult patients with plaque psoriasis =
is 320 mg (given as two subcutaneous injections of 160 mg) at week 0, 4, 8,=
12, 16 and every eight weeks thereafter.3 For some patients with a body we=
ight=E2=89=A5120 kg who did not achieve complete skin clearance at week 16,=
320 mg every 4 weeks after week 16 may further improve treatment response.=
3 In the studies reported at EADV 2022, patients received maintenance dosin=
g of bimekizumab 320 mg Q4W or Q8W.
=C2=A5 Modified non-responder imputation analyses
Notes to editors :
About BE BRIGHT
BE BRIGHT (NCT03598790) is an ongoing, multicentre, open-label extension st=
udy assessing the long-term safety, tolerability and efficacy of bimekizuma=
b in adult patients with moderate to severe chronic plaque psoriasis. =C2=
=A0Patients who completed one of three bimekizumab Phase 3 studies, BE READ=
Y, BE VIVID and BE SURE, were eligible to enrol in the BE BRIGHT study.^4 M=
ore details on BE BRIGHT can be found at ClinicalTrials.gov (https://clinic=
altrials.gov/ct2/show/NCT03598790) .^4
BE VIVID, BE READY and BE SURE evaluated the efficacy and safety of bimekiz=
umab in the treatment of adults with moderate to severe plaque psoriasis ve=
rsus placebo and ustekinumab, versus placebo, and versus adalimumab, respec=
tively.^5,6,7=C2=A0=C2=A0
About psoriasis
Psoriasis is a chronic inflammatory disease with primary involvement of the=
skin.^8 Psoriasis signs and symptoms can vary but may include red patches =
of skin covered with silvery scales; dry, cracked skin that may bleed; and =
thickened, pitted or ridged nails.^9 Psoriasis also has a considerable psyc=
hological and quality-of-life impact, potentially affecting work, recreatio=
n, relationships, sexual functioning, family and social life.^10 This skin =
condition affects men and women of all ages and ethnicities.^8=C2=A0
About bimekizumab
Bimekizumab is a humanized monoclonal IgG1 antibody that is designed to sel=
ectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F)=
, two key cytokines driving inflammatory processes.^3,11=C2=A0
In August 2021, bimekizumab was approved in the European Union (EU)/Europea=
n Economic Area (EEA) and in Great Britain, for the treatment of moderate t=
o severe plaque psoriasis in adults who are candidates for systemic therapy=
^3,12=C2=A0 The label information may differ in other countries. Please che=
ck local prescribing information.
BIMZELX^=C2=AE=E2=96=BC=C2=A0(bimekizumab) EU/EEA Important Safety Informat=
ion in Psoriasis
The most frequently reported adverse reactions with bimekizumab were upper =
respiratory tract infections (14.5%) (most frequently nasopharyngitis) and =
oral candidiasis (7.3%). Common adverse reactions (=E2=89=A51/100 to <1/10)=
were oral candidiasis, tinea infections, ear infections, herpes simplex in=
fections, oropharyngeal candidiasis, gastroenteritis, folliculitis, headach=
e, dermatitis and eczema, acne, injection site reactions, fatigue. Elderly =
may be more likely to experience certain adverse reactions such as oral can=
didiasis, dermatitis and eczema when using bimekizumab.
Bimekizumab is contraindicated in patients with hypersensitivity to the act=
ive substance or any of the excipients and in patients with clinically impo=
rtant active infections (e.g. active tuberculosis).=C2=A0
Bimekizumab may increase the risk of infections. Treatment with bimekizumab=
must not be administered in patients with any clinically important active =
infection. Patients treated with bimekizumab should be instructed to seek m=
edical advice if signs or symptoms suggestive of an infection occur. Prior =
to initiating treatment with bimekizumab, patients should be evaluated for =
tuberculosis (TB) infection. Bimekizumab should not be given in patients wi=
th active TB and patients receiving bimekizumab should be monitored for sig=
ns and symptoms of active TB.=C2=A0
Cases of new or exacerbations of inflammatory bowel disease have been repor=
ted with bimekizumab. Bimekizumab is not recommended in patients with infla=
mmatory bowel disease. If a patient develops signs and symptoms of inflamma=
tory bowel disease or experiences an exacerbation of pre-existing inflammat=
ory bowel disease, bimekizumab should be discontinued and appropriate medic=
al management should be initiated. Serious hypersensitivity reactions inclu=
ding anaphylactic reactions have been observed with IL-17 inhibitors. If a =
serious hypersensitivity reaction occurs, administration of bimekizumab sho=
uld be discontinued immediately and appropriate therapy initiated.=C2=A0
Live vaccines should not be given in patients treated with bimekizumab.
Please consult the summary of product characteristics in relation to other =
side effects, full safety and prescribing information. https://www.ema.euro=
pa.eu/en/documents/product-information/bimzelx-epar-product-information_en.=
pdf
EU summary of product characteristics date of revision March 2022.
Last accessed: August 2022.
=E2=96=BCThis medicinal product is subject to additional monitoring. This w=
ill allow quick identification of new safety information. Healthcare profes=
sionals are asked to report any suspected adverse reactions=C2=A0
For further information, contact UCB:=C2=A0
Investor Relations
Antje Witte
T +32.2.559.94.14=C2=A0
email antje.witte@ucb.com=C2=A0
Corporate Communications
Laurent Schots=C2=A0
T +32.2.559.92.64=C2=A0
email laurent.schots@ucb.com
Brand Communications
Eimear O=E2=80=99Brien
T +32.2.559.92.71
email eimear.obrien@ucb.com=C2=A0
About UCB=C2=A0
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With approximately 8,600 peopl=
e in approximately 40 countries, the company generated revenue of =E2=82=AC=
5.8 billion in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Foll=
ow us on Twitter: @UCB_news.
Forward looking statements=C2=A0
This press release may contain forward-looking statements including, withou=
t limitation, statements containing the words =E2=80=9Cbelieves=E2=80=9D, =
=E2=80=9Canticipates=E2=80=9D, =E2=80=9Cexpects=E2=80=9D, =E2=80=9Cintends=
=E2=80=9D, =E2=80=9Cplans=E2=80=9D, =E2=80=9Cseeks=E2=80=9D, =E2=80=9Cestim=
ates=E2=80=9D, =E2=80=9Cmay=E2=80=9D, =E2=80=9Cwill=E2=80=9D, =E2=80=9Ccont=
inue=E2=80=9D and similar expressions. These forward-looking statements are=
based on current plans, estimates and beliefs of management. All statement=
s, other than statements of historical facts, are statements that could be =
deemed forward-looking statements, including estimates of revenues, operati=
ng margins, capital expenditures, cash, other financial information, expect=
ed legal, arbitration, political, regulatory or clinical results or practic=
es and other such estimates and results. By their nature, such forward-look=
ing statements are not guarantees of future performance and are subject to =
known and unknown risks, uncertainties and assumptions which might cause th=
e actual results, financial condition, performance or achievements of UCB, =
or industry results, to differ materially from those that may be expressed =
or implied by such forward-looking statements contained in this press relea=
se. Important factors that could result in such differences include: the gl=
obal spread and impact of COVID-19, changes in general economic, business a=
nd competitive conditions, the inability to obtain necessary regulatory app=
rovals or to obtain them on acceptable terms or within expected timing, cos=
ts associated with research and development, changes in the prospects for p=
roducts in the pipeline or under development by UCB, effects of future judi=
cial decisions or governmental investigations, safety, quality, data integr=
ity or manufacturing issues; potential or actual data security and data pri=
vacy breaches, or disruptions of our information technology systems, produc=
t liability claims, challenges to patent protection for products or product=
candidates, competition from other products including biosimilars, changes=
in laws or regulations, exchange rate fluctuations, changes or uncertainti=
es in tax laws or the administration of such laws, and hiring and retention=
of its employees. There is no guarantee that new product candidates will b=
e discovered or identified in the pipeline, will progress to product approv=
al or that new indications for existing products will be developed and appr=
oved. Movement from concept to commercial product is uncertain; preclinical=
results do not guarantee safety and efficacy of product candidates in huma=
ns. So far, the complexity of the human body cannot be reproduced in comput=
er models, cell culture systems or animal models. The length of the timing =
to complete clinical trials and to get regulatory approval for product mark=
eting has varied in the past and UCB expects similar unpredictability going=
forward. Products or potential products, which are the subject of partners=
hips, joint ventures or licensing collaborations may be subject to differen=
ces disputes between the partners or may prove to be not as safe, effective=
or commercially successful as UCB may have believed at the start of such p=
artnership. UCB=E2=80=99s efforts to acquire other products or companies an=
d to integrate the operations of such acquired companies may not be as succ=
essful as UCB may have believed at the moment of acquisition. Also, UCB or =
others could discover safety, side effects or manufacturing problems with i=
ts products and/or devices after they are marketed. The discovery of signif=
icant problems with a product similar to one of UCB=E2=80=99s products that=
implicate an entire class of products may have a material adverse effect o=
n sales of the entire class of affected products. Moreover, sales may be im=
pacted by international and domestic trends toward managed care and health =
care cost containment, including pricing pressure, political and public scr=
utiny, customer and prescriber patterns or practices, and the reimbursement=
policies imposed by third-party payers as well as legislation affecting bi=
opharmaceutical pricing and reimbursement activities and outcomes. Finally,=
a breakdown, cyberattack or information security breach could compromise t=
he confidentiality, integrity and availability of UCB=E2=80=99s data and sy=
stems.=C2=A0
Given these uncertainties, you should not place undue reliance on any of su=
ch forward-looking statements. There can be no guarantee that the investiga=
tional or approved products described in this press release will be submitt=
ed or approved for sale or for any additional indications or labelling in a=
ny market, or at any particular time, nor can there be any guarantee that s=
uch products will be or will continue to be commercially successful in the =
future.
UCB is providing this information, including forward-looking statements, on=
ly as of the date of this press release and it does not reflect any potenti=
al impact from the evolving COVID-19 pandemic, unless indicated otherwise. =
UCB is following the worldwide developments diligently to assess the financ=
ial significance of this pandemic to UCB. UCB expressly disclaims any duty =
to update any information contained in this press release, either to confir=
m the actual results or to report or reflect any change in its forward-look=
ing statements with regard thereto or any change in events, conditions or c=
ircumstances on which any such statement is based, unless such statement is=
required pursuant to applicable laws and regulations.=C2=A0
Additionally, information contained in this document shall not constitute a=
n offer to sell or the solicitation of an offer to buy any securities, nor =
shall there be any offer, solicitation or sale of securities in any jurisdi=
ction in which such offer, solicitation or sale would be unlawful prior to =
the registration or qualification under the securities laws of such jurisdi=
ction.=C2=A0
References
1. Strober B, Tada Y, Mrowietz U et al. Bimekizumab maintenance of response=
through three years in patients with moderate to severe plaque psoriasis w=
ho responded at Week 16: Results from the BE BRIGHT open-label extension tr=
ial. Abstract presented at the 31st EADV Congress.
2. Gordon KB, Langley RG, Warren RB et al. Bimekizumab safety in patients w=
ith moderate to severe plaque psoriasis: Analysis of pooled data from up to=
three years of treatment in phase 2 and 3 clinical trials. Abstract presen=
ted at the 31st EADV Congress.
3. BIMZELX (bimekizumab) EU Summary of Product Characteristics, March 2022.=
Available at: https://www.ema.europa.eu/en/documents/product-information/b=
imzelx-epar-product-information_en.pdf Last accessed: August 2022.=C2=A0
4. ClinicalTrials.gov. A Study to Evaluate the Efficacy and Safety of Bimek=
izumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (=
BE BRIGHT). Available at: https://clinicaltrials.gov/ct2/show/NCT03598790 L=
ast accessed: August 2022.
=C2=A0
5. Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for =
the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy a=
nd safety from a 52-week, multicentre, double-blind, active comparator and =
placebo-controlled phase 3 trial. Lancet. 2021;397(10273):487-498.
6. Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety i=
n moderate to severe plaque psoriasis (BE READY): a multicentre, double-bli=
nd, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021;3=
97(10273):475-486.
7. Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus Adalimumab in =
Plaque Psoriasis. N Engl J Med. 2021;385(2):130-141.
8. National Psoriasis Foundation. About Psoriasis. Available at: https://ww=
w.psoriasis.org/about-psoriasis/ Last accessed: August 2022.
9. NHS. Psoriasis Symptoms. Available at: https://www.nhs.uk/conditions/pso=
riasis/symptoms/ (https://www.psoriasis.org/about-psoriasis/) . Last access=
ed: August 2022.
10. Moon HS, Mizara A, McBride SR. Psoriasis and psycho-dermatology. Dermat=
ol Ther (Heidelb). 2013;3(2):117-130.
11. Glatt S, Helmer E, Haier B, et al. First-in-human randomized study of b=
imekizumab, a humanized monoclonal antibody and selective dual inhibitor of=
IL-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol. 2017;83(5):991-=
1001.
12. BIMZELX^=C2=AE (bimekizumab) GB Summary of Product Characteristics. Ava=
ilable at: https://www.medicines.org.uk/emc/product/12834;=C2=A0https://www=
.medicines.org.uk/emc/product/12833 Last accessed: August 2022.
GenericFile
UCB PR EADV Sept 7 2022 ENG (https://mb.cision.com/Public/18595/3626545/abb=
4a5b07f176202.pdf)
______________________
If you would rather not receive future communications from UCB SA, please g=
o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x115094x1x6868579x2400=
0x6&Email=3Dregnews%40symexglobal.com.
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium